A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)
Latest Information Update: 01 Jan 2024
At a glance
- Drugs Sprifermin (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms FORWARD
- Sponsors EMD Serono; Merck KGaA
- 15 Nov 2023 Results of a post-hoc analysis assessing effect of sprifermin on the symptomatic progression of knee OA (KOA) were presented at the ACR Convergence 2023.
- 15 Nov 2023 Results of a post-hoc analysis assessing clinical and structural data from this study participants who underwent knee replacement in year 3-5 presented at the ACR Convergence 2023
- 15 Nov 2023 Results of post hoc analysis investigating the impact of sprifermin treatment on dABs in KOA, presented at the ACR Convergence 2023